MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma
The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Loss of membrane MHC class I protein expression in most of tumor cells in advanced melanomas predicts primary resistance to anti–CTLA-4, but not anti-PD1, treatment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In another study, MHC I downregulation via transcriptional repression was associated with primary resistance to anti-CTLA-4 therapy but not to anti-PD-1 therapy, and the response to anti-PD-1 was more dependent on MHC II expression linked to an IFN-γ-regulated module of genes (97).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [97]
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
GSVA: gene set variation analysis for microarray and RNA-Seq data
Hänzelmann, S., Castelo, R., & Guinney, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-7 · Cited by 15,440
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationSalmon provides fast and bias-aware quantification of transcript expression
Patro, R., Duggal, G., Love, M. I., Irizarry, R. A., & Kingsford, C. (2017) · Nature Methods · doi:10.1038/nmeth.4197 · Cited by 12,700
Cingolani, P., Platts, A., Wang, L. L., Coon, M., Nguyen, T., Wang, L., Land, S. J., Lu, X., & Ruden, D. M. (2012) · Fly · doi:10.4161/fly.19695 · Cited by 11,816
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Cited by
Items 401–500 of 623
Advances in cancer immunotherapy: adoptive cell therapy and immune cell engagers in solid tumours
Panasci, J., Park, C. L., Tran, B., & Siu, L. L. (2026) · British Journal of Cancer · doi:10.1038/s41416-026-03450-w · Cited by 8
Gong, X., Li, N., Sun, C., Li, Z., & Xie, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.874780 · Cited by 8
Liu, Z., Wan, R., Bai, H., & Wang, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104560 · Cited by 8
Cediranib enhances the transcription of MHC-I by upregulating IRF-1
Zhang, J., Guo, H., Wang, L., Zheng, M., Kong, S., Wu, H., Zhao, L., Zhao, Q., Yang, X., He, Q., et al. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116036 · Cited by 8
Deciphering CD4+ T cell‐mediated responses against cancer
Kirkpatrick, C. A., & Lu, Y. (2024) · Molecular Carcinogenesis · doi:10.1002/mc.23730 · Cited by 8
Uncoupling tumor immunogenicity from cell death with platinum(IV)–antibody conjugates
Liu, L., Yu, W., Liu, Y., Yang, Y., Wei, Q., Zhao, Z., Yang, R., Li, J. P., & Guo, Z. (2026) · National Science Review · doi:10.1093/nsr/nwag202 · Cited by 8
Gulhan, D., Viswanadham, V., Muyas, F., Jin, H., Foote, M. B., Lee, J. J.-K., Barras, D., Jung, Y. L., Ljungström, V., Rousseau, B., et al. (2024) · medRxiv · doi:10.1101/2024.01.19.24301236 · Cited by 8
Koukoulias, K., Papayanni, P. G., Jones, J., Kuvalekar, M., Watanabe, A., Velazquez, Y., Gilmore, S. A., Παπαδοπούλου, Α., Leen, A. M., & Vasileiou, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1299512 · Cited by 8
Chen, M., Zeng, Y., & Zhao, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.893490 · Cited by 8
Lee, L. H., Xu, X., Mourikis, T. P., Tang, F., Fairchild, L., Ji, L., Grauel, A. L., Wagner, J. P., Szpakowski, S., Pelletier, M. R., et al. (2025) · Cancer Research Communications · doi:10.1158/2767-9764.crc-24-0605 · Cited by 8
Wang, J., Wu, Z., Zheng, M., Yu, S., Zhang, X., & Xu, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.1025306 · Cited by 9
Butt, N. S., Kurdi, M. E., Fadul, M. M., Hakamy, S., Addas, B. M. J., Faizo, E., Alkhayyat, S. S., Bamaga, A. K., Alsinani, T., Katib, Y., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154816 · Cited by 8
Li, H., Li, Y., Wang, C., Wang, S., & Ho, M. (2019) · Antibody Therapeutics · doi:10.1093/abt/tbz010 · Cited by 8
Breaking the mold: Overcoming resistance to immune checkpoint inhibitors
Zhao, M., Yan, C.-Y., Wei, Y.-N., & Zhao, X. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105720 · Cited by 7
Genomics-based immuno-oncology: bridging the gap between immunology and tumor biology
DiNatale, R. G., Hakimi, A. A., & Chan, T. A.-T. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa203 · Cited by 7
Sun, J.-R., Kong, C., Qu, X.-K., Sun, A.-T., Kun-peng, Z., & Sun, J. (2023) · Aging · doi:10.18632/aging.204534 · Cited by 7
Lautert-Dutra, W., Melo, C. M., Chaves, L. P., Crozier, C., Saggioro, F. P., dos Reis, R. B., Bayani, J., Bonatto, S. L., & Squire, J. A. (2024) · Molecular Cytogenetics · doi:10.1186/s13039-024-00680-6 · Cited by 7
Tumor antigen presentation and the associated signal transduction during carcinogenesis
Naskar, S., Sriraman, N., Sarkar, A., Mahajan, N., & Sarkar, K. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155485 · Cited by 7
MEST promotes immune escape in gastric cancer by downregulating MHCI expression via SHP2
Huang, M., Zhang, F., Zhu, Y., Zeng, H., & Li, S. (2024) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2024.106621 · Cited by 7
Xu, L., Xiao, T., Chao, T., Xiong, H., & Yao, W. (2025) · BMC Cancer · doi:10.1186/s12885-025-14306-6 · Cited by 7
Overcoming melanoma resistance to immune checkpoint blockade therapy using nano-strategies
Ding, Y., Liu, C., Wu, Y., & Fu, F. (2023) · Biomedical Technology · doi:10.1016/j.bmt.2023.03.003 · Cited by 7
Sam, I., Benhamouda, N., Biard, L., Meda, L. D., Desseaux, K., Baroudjan, B., Nakouri, I., Renaud, M., Sadoux, A., Alkatrib, M., et al. (2025) · EMBO Molecular Medicine · doi:10.1038/s44321-025-00203-9 · Cited by 7
Dent, R. A., Cortés, J., Park, Y. H., Muñoz‐Couselo, E., Kim, S., Sohn, J., Im, S., Holgado, E., Foukakis, T., Kümmel, S., et al. (2025) · Breast Cancer Research · doi:10.1186/s13058-024-01946-y · Cited by 7
Transcriptomic era of cancers in females: new epigenetic perspectives and therapeutic prospects
Zhu, R., Ni, J., Ren, J., Li, D., Xu, J., Yu, X., Ma, Y. J., & Kou, L. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1464125 · Cited by 7
BCL7B, a SWI/SNF complex subunit, orchestrates cancer immunity and stemness
Higuchi, S., Suehiro, Y., Izuhara, L., Yoshina, S., Hirasawa, A., & Mitani, S. (2023) · BMC Cancer · doi:10.1186/s12885-023-11321-3 · Cited by 7
Inactivating mutations of class II transactivator (CIITA) gene in gastric and colorectal cancers
Son, H. J., Choi, E. J., Yoo, N. J., & Lee, S. H. (2020) · Pathology - Research and Practice · doi:10.1016/j.prp.2020.153110 · Cited by 7
CD4+ conventional T cells-related genes signature is a prognostic indicator for ovarian cancer
Hua, T., Liu, D.-X., Zhang, X.-C., Li, S.-T., Yan, P., Zhao, Q., & Chen, S.-B. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1151109 · Cited by 6
Tanegashima, T., Shiota, M., Fujiyama, N., Narita, S., Habuchi, T., Fukuchi, G., Takamatsu, D., Oda, Y., Miyake, H., Takahashi, M., et al. (2024) · The Journal of Immunology · doi:10.4049/jimmunol.2300308 · Cited by 6
Molecular Mechanisms of Immune Checkpoints as an Immunotherapy Tool in Hematological Malignancies
Gezici, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00035-4 · Cited by 6
Sun, J.-L., Chu, Y.-C., Wang, F., Yu, D.-D., Liu, J.-R., Xu, R.-C., Liu, H., Qi, Z., Shi, X., Yu, X., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102774 · Cited by 7
Balasubramanian, A., Marceaux, C., Kanwal, S., Tarasova, I., Batey, D., Senko, C., Asadi, K., Yokote, K., Palmer, J., Christie, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1449 · Cited by 6
Sun, Y., Yang, B., Wen, T., Guo, X., Li, D., Shi, R., Zhang, F., Wang, D., Li, C., & Qu, X. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-024-09982-2 · Cited by 6
Slotta‐Huspenina, J., Schwamborn, K., Steiger, K., Simon, R., Kirchhoff, F. P., Büchler, J., Fiedler, J., Retz, M. M., Nawroth, R., Ritschel, C., et al. (2022) · Bladder Cancer · doi:10.3233/blc-211604 · Cited by 6
Khalil, M. I., Wang, J., Vu, L., Yang, C., Yin, C., Chadha, S., Nabors, H., Vocelle, D. B., May, D. G., Chrisopulos, R. J., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2525730123 · Cited by 6
MHC class II genotypes are independent predictors of anti-PD1 immunotherapy response in melanoma
Claeys, A., & den Eynden, J. V. (2024) · Communications Medicine · doi:10.1038/s43856-024-00612-w · Cited by 6
Zhang, H., Dong, W., Zhao, H., Zeng, Z., Zhang, F., Hu, Y., Li, Q., Chen, J., Meng, E., & Xiao, W. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-3825 · Cited by 6
Sverchkova, A., Burkholz, S., Rubsamen, R., Stratford, R., & Clancy, T. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01808-8 · Cited by 6
Novikova, E. M., Chukhina, E. S., Razvalyayeva, N. A., Козырева, О. В., Golovina, M. E., Леонидович, Л. В., Aparin, P. G., & Stepanenko, R. N. (2024) · Immunologiya · doi:10.33029/1816-2134-2024-45-1-68-81 · Cited by 6
Vyhnánková, S., Lacina, L., Chovanec, M., Plzák, J., Smetana, K., Netušil, J., Kolář, M., & Šindelka, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188844 · Cited by 5
Yamazawa, S., Fukasawa, M., Takase, A., Kondo, A., Matsubara, J., Shinozaki‐Ushiku, A., Seto, Y., & Ushiku, T. (2025) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-025-04108-3 · Cited by 5
Zhang, H., Wang, Y., Wang, K., Ding, Y., Li, X., Zhao, S., Jia, X., & Sun, D. (2023) · Aging · doi:10.18632/aging.204838 · Cited by 5
Monti, M., Picinoli, S., Bozzola, A. M., Ferrari, M., Bugatti, M., Pezzali, I., Carlomagno, M., Carta, G., Orlandi, M., Lora, G., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012222 · Cited by 5
Wang, B., Li, J., Li, X., & Ou, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.10681 · Cited by 5
Moore, C., Bae, J., Liu, L., Li, H., Fu, Y., & Qiao, J. (2022) · JCI Insight · doi:10.1172/jci.insight.159479 · Cited by 5
Schweihofer, V., Bruß, C., Seitz, S., Glehr, G., Hetterich, M., Weber, F., Hatzipanagiotou, M. E., Fernandez-Pacheco, M., Ortmann, O., Brockhoff, G., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03729-7 · Cited by 5
Bao, L., Zhu, M., Luo, M., Kumar, A., Peng, Y., Xing, C., Wang, Y., & Luo, W. (2025) · Journal of Clinical Investigation · doi:10.1172/jci188801 · Cited by 5
Mei, S., Liu, J., Huang, Z., Luo, W., Peng, Y., Chen, Z., Deng, Y., Xu, C., & Zhou, Q. H. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15299 · Cited by 5
S-nitrosylation of IRF7 induced by NOS1 expression in melanoma suppresses anti-tumor immunity
Dai, Y., Zeng, S., Li, K., Huang, J., Yang, M., Gao, W., Chen, X., Huang, M., Ye, S., Wang, Q., et al. (2026) · Cell Death and Disease · doi:10.1038/s41419-025-08201-y · Cited by 5
The potential applications of peptide-loading complex in cancer treatment
Song, Z., Tao, Y., & You, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1526137 · Cited by 5
Cytokines: Signalling Improved Immunotherapy?
Luca, A. D., Lyons, A. B., & Flies, A. S. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01095-x · Cited by 5
Immunotherapy and predictive immunologic profile: the tip of the iceberg
Pereira, T. C., Rodrigues‐Santos, P., Almeida, J. S., Salgueiro, F. R., Monteiro, A. R., Macedo, F., Soares, R. F., Domingues, I., Jacinto, P., & Sousa, G. (2021) · Medical Oncology · doi:10.1007/s12032-021-01497-8 · Cited by 4
Kang, H., Nie, H., He, A., Zheng, S.-X., Zhu, H.-Y., Li, Z., Hou, Z.-Y., Liu, H.-M., Zhang, X., Ma, L., et al. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115076 · Cited by 4
The necessary role of an efficient tumor immunotherapy by MHC II expression on amateur APCs
Zhong, J., Lin, X., & Hu, H. (2024) · Malignancy Spectrum · doi:10.1002/msp2.29 · Cited by 4
EPRIM: An approach of identifying cancer immune-related epigenetic regulators
Shi, A., Lin, C., Wang, J., Chen, Y., Zhong, J., & Lyu, J. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.102100 · Cited by 4
The Transcriptional Landscape of BRAF Wild Type Metastatic Melanoma: A Pilot Study
Lastraioli, E., Ruffinatti, F. A., Bagni, G., Visentin, L., Costanzo, F. D., Munaron, L., & Arcangeli, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136898 · Cited by 4
Mullen, N. J., Shukla, S. K., Thakur, R. K., Kollala, S. S., Wang, D., Chaika, N. V., Santana, J. F., Miklavcic, W. R., LaBreck, D. A., Mallareddy, J. R., et al. (2024) · eLife · doi:10.7554/elife.87292.2 · Cited by 4
Ju, Y., Zhang, J., Deng, J., Wu, X., Yang, H., Tao, C., & Li, X. (2025) · Cancer Cell International · doi:10.1186/s12935-025-04056-7 · Cited by 4
Selective activation of IFNγ–ipilimumab enhances the therapeutic effect and safety of ipilimumab
Huang, Y.-J., Ho, K., Cheng, T., Wang, Y., Chao, S.-W., Huang, B.-C., Chao, Y.-S., Lin, C.-Y., Hsu, Y.-H., Chen, F., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.130945 · Cited by 4
Qi, L., Jiang, K.-Y., Zhao, F.-F., Ren, P., & Wang, L. (2024) · Scientific Reports · doi:10.1038/s41598-023-50758-1 · Cited by 4
Comprehensive screening for drugs that modify radiation-induced immune responses
Okumura, M., Du, J., Kageyama, S., Yamashita, R., Hakozaki, Y., Motegi, A., Hojo, H., Nakamura, M., Hirano, Y., Okuma, Y., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-021-01688-0 · Cited by 4
Balko, J. M., Licata, L., Wang, X. Q., Dugo, M., Huang, C., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Antón, A., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00828-6 · Cited by 4
Zhou, L., Xu, L., & Qiao, G. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03574-6 · Cited by 4
Yamada, R., Kawakami, F., Maeda, N., Nagao, S., Yamamoto, M., Motohara, T., Kondoh, E., Mikami, Y., & Komohara, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156146 · Cited by 4
Vallacchi, V., Vergani, E., Cossa, M., Gargiuli, C., Busico, A., Devecchi, A., Dugo, M., Bergamaschi, L., Cecco, L. D., Cavalieri, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007612 · Cited by 4
Roldan-Marin, R., Rangel‐Gamboa, L., Vega-Memije, M. E., Hernández-Doño, S., Ruiz-Gómez, D., & Granados, J. (2021) · Indian Journal of Dermatology Venereology and Leprology · doi:10.25259/ijdvl_627_19 · Cited by 4
MHC expression predicts response
Sidaway, P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0082-3 · Cited by 4
Ványai, B., Chien, Y.-C. C., Beke, L., Szabó, I. L., Péter, Z., Steuer-Hajdú, K., Várvölgyi, T., Méhes, G., & Emri, G. (2022) · Immunotherapy · doi:10.2217/imt-2022-0113 · Cited by 4
Liu, K., Huang, T., Zhang, H., Deng, H., & Tang, M. (2022) · Scientific Reports · doi:10.1038/s41598-022-26490-7 · Cited by 4
Beitraege zur Systematik der Tribus Mesochorini Japans (Hym. Ichneumonidae)
Uchida, T. (1933) · Insecta Matsumurana · Cited by 3
Immunotherapy for Pancreatic Cancer
Sunami, Y., Rieder, S., Michl, P., & Kleeff, J. H. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_223-1 · Cited by 3
Boccarelli, A., Buono, N. D., & Esposito, F. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084406 · Cited by 3
Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors
Jiang, S., Geng, S., Luo, X., Zhang, C., Yu, Y., Cheng, M., Zhang, S., Shi, N., & Dong, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.995785 · Cited by 3
Herold, N., Bochem, J., Leyens, J., Wingerter, S., Forchhammer, S., Spreuer, J., Deseke, M., Yurttas, C., Nocerino, P., Reis, R. A. D., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011224 · Cited by 3
Evolutionary trajectories of immune escape across cancersPreprint
Chen, W., Baker, T. M., Zhang, Z., Ogilvie, H. A., Loo, P. V., & Gu, S. S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.01.17.632799 · Cited by 3
Mezzanotte-Sharpe, J., Taylor, B. C., Ericsson, P. I. G., Sanchez, V. M., Ocampo, A. A., Marshall, J. L., Steele, J. A., Sanders, M. E., Mayer, I. A., Balko, J. M., et al. (2025) · npj Breast Cancer · doi:10.1038/s41523-025-00773-4 · Cited by 3
Middleton, G., Gaskell, C., Savage, J., Bridgewater, J. A., Ross, P. J., Saunders, M. P., Palmer, D. H., Plummer, R., Clive, S., Coyle, V. M., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-012749 · Cited by 3
Jin, Y., Zheng, W., Zhang, R., Hou, S., Luo, C., Ren, P., Pan, D., Luo, C., & Zeng, Z. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-026-03673-y · Cited by 3
Identification of Immune Function-Related Subtypes in Cutaneous Melanoma
Liu, L., Zhu, J., Jin, T., Huang, M., Chen, Y., Xu, L., Chen, W., Jiang, B., & Yan, F. (2021) · Life · doi:10.3390/life11090925 · Cited by 3
MHC class II: a predictor of outcome in melanoma treated with immune checkpoint inhibitors
Amrane, K., Noach, P., Hémon, P., Abgral, R., Meur, C. L., Pradier, O., Misery, L., Legoupil, D., Berthou, C., & Uguen, A. (2025) · Melanoma Research · doi:10.1097/cmr.0000000000001022 · Cited by 3
HLA-monomorphic determinants of the primary tumor in breast cancer patients
Чулкова, С. В., Шолохова, Е. Н., Poddubnaya, I. V., Stylidi, I. S., & Tupitsyn, N. N. (2022) · Russian Journal of Biotherapy · doi:10.17650/1726-9784-2022-21-2-56-66 · Cited by 3
Immunotherapy in surgical oncology
Reynolds, I. S., & Fennelly, D. W. (2022) · British journal of surgery · doi:10.1093/bjs/znac385 · Cited by 3
Ladd, S., Talkington, A., O’Sullivan, M., Barnes, R. W., Wessel, R. E., Hanson, G. F., & Dolatshahi, S. (2025) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-025-00857-y · Cited by 2
Immuno-oncology approaches to overcome T cell exhaustion in melanoma
El-Sehrawy, A. A. M. A., Alshahrani, M. Y., Fedwi, M. M., Ganesan, S., Al-Khafaji, Z., Arora, V., Pal, A., Nayak, P. P., Islomov, S., & Hsu, C. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152454 · Cited by 2
Understanding the Promise and Challenges of Tumor-Agnostic Therapy: Could One Size Really Fit All?
Myat, Y. M., Thein, K. Z., Han, M. M., Ahluwalia, M. S., Mukherjee, S., & Aung, K. L. (2026) · Cancers · doi:10.3390/cancers18101568 · Cited by 2
Lee, C., DiNatale, R. G., Chowell, D., Krishna, C., Makarov, V., Valero, C., Vuong, L. H., Lee, M., Weiss, K. L., Hoen, D., et al. (2023) · doi:10.1158/1541-7786.c.6545243 · Cited by 2
Modern aspects of immunotherapy with checkpoint inhibitors in melanoma
Vladimirova, L. Y., Teplyakova, M. A., Попова, И. Л., Абрамова, Н. А., Tikhanovskaya, N. M., Льянова, А. А., Эдуардовна, С. А., Алексеевна, Р. Л., Kabanov, S. N., Kalabanova, E. A., et al. (2022) · Medical alphabet · doi:10.33667/2078-5631-2022-26-35-40 · Cited by 2
Ge, W., Zhang, Z., Chen, W., Zhao, Z., Cai, H., Ding, Y., & Xu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1662869 · Cited by 2
Bestion, E., Rachid, M., Tijeras‐Raballand, A., Roth, G. S., Decaens, T., Ansaldi, C., Mezouar, S., Raymond, É., & Halfon, P. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.18.524541 · Cited by 2
Schoenfeld, J. D., Azad, N. S., Gross, J., Chen, L., Overman, M. J., Kao, K. Z., Jackson, L., Brunnquell, D., Bu, X., Coppola, C., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0427 · Cited by 2
Self-citationFeng, J., Liang, B., Zheng, W., Xu, L., Zhou, Q., & Chen, J. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03714-5 · Cited by 2
Xu, H., Hu, Y., Peng, X., & Chen, E. (2023) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2023.2261146 · Cited by 2
Hegyi, B., Csikó, K. G., Balatoni, T., Fröhlich, G., Bőcs, K., Tóth, E., Mohos, A., Neumark, A. R., Menyhárt, C. D., Ferrone, S., et al. (2024) · Biomolecules · doi:10.3390/biom14121609 · Cited by 2
Bentebibel, S.-E., McGrail, D. J., Kochat, V., Arslan, E., Abdel‐Wahab, R., Pazdrak, B., Murthy, R., Tahon, N. H., Cho, S. H., Duose, D. Y., et al. (2026) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-1551 · Cited by 2
Lautert-Dutra, W., Melo, C. M., Chaves, L. P., Crozier, C., Saggioro, F. P., dos Reis, R. B., Bayani, J., Bonatto, S. L., & Squire, J. A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.16.487364 · Cited by 2
Schmiechen, Z. C., Cruz-Hinojoza, E., Hilk, A. L., Ellefson, M. A., Tsai, A. K., Dres, O. M., Kang, L., Geuenich, M. J., Butler, J. Z., Burrack, A. L., et al. (2026) · Science Immunology · doi:10.1126/sciimmunol.adz4302 · Cited by 2
Programmable mRNA 3′UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer
Huang, F., Yuan, F., Li, K., Cui, Y., Li, L., Ye, W., Cui, Z., Yan, J., Chen, Q., Nicchitta, C. V., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-026-01720-9 · Cited by 2
Mizuno, S., Mizuno, Y., Abe, K., Macy, A. M., Chong, K. K., Kobayashi, Y., Hastings, K. T., Hoon, D. S. B., & Bustos, M. A. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02710-9 · Cited by 2
Georgopoulos, A. P., & James, L. M. (2025) · Exploration of Medicine · doi:10.37349/emed.2025.1001375 · Cited by 2
“RIPping” off Pancreas Cancer's Blockage of Immune Surveillance
Liu, X., Sells, B. E., & DeNardo, D. G. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1361 · Cited by 2
Zhang, C., Wang, K., & Wang, H. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-03019-6 · Cited by 2
Metadata
- Authors
- Rodig, S. J., Gusenleitner, D., Jackson, D. G., Gjini, E., Giobbie-Hurder, A., Jin, C., Chang, H., Lovitch, S. B., Horak, C., Weber, J. S., Weirather, J. L., Wolchok, J. D., Postow, M. A., Pavlick, A. C., Chesney, J., & Hodi, F. S.
- Affiliations
- Brigham and Women's Hospital (US)
- Dana-Farber Cancer Institute (US)
- Bristol-Myers Squibb (United States) (US)
- Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- NYU Langone Health (US)
- Memorial Sloan Kettering Cancer Center (US)
- University of Louisville (US)
- Corresponding author
- Rodig, Scott J.
- Hodi, F. Stephen
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-07-18
- Volume
- 10
- Issue
- 450
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W2883970691
- Cited by
- 579
- References
- 59
- Citations by year
- 2026: 38 · 2025: 48 · 2024: 75 · 2023: 101 · 2022: 94 · 2021: 79 · 2020: 76 · 2019: 55 · 2018: 12
- FWCI
- 20.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Funded by Bristol-Myers Squibb (N/A)
- NIH/NCI Cancer Center (P30 CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- metastatic melanoma, MHC class I expression, MHC class II expression, CTLA-4 blockade, anti-PD-1 therapy, immune checkpoint inhibitors, interferon-gamma, innate immunity, tumor antigen presentation, antitumor immunity, predictive biomarkers
- MeSH terms
- HLA Antigens, Humans, Immunity, Innate, Immunotherapy, Melanoma, Transcription, Genetic, Gene Expression Regulation, Neoplastic, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.